Skip to content

Contact Us Select Models

Services
Preclinical Research
Clinical Research
Assays
Data
Lumin
Resources
Events
Company
Company
Investors
- Investor Relations

Contact Us Select Models

Trends in Oncology

Radiopharmaceutical

Radiopharmaceutical Efficacy Studies in PDX Models: Why Tumor Diversity Matters

Radiopharmaceutical

Radiochemistry 101 for ADC Teams: A Practical Guide for Biodistribution Studies

Radiopharmaceutical

FDA Guidance: The Future of Radiopharmaceutical Development

Radiopharmaceutical

Radiopharmaceuticals in Cancer Treatment: Insights from Mike Ritchie

Radiopharmaceutical

Seeing Beyond Efficacy: How Radiolabeling Advances ADC Drug Development

Radiopharmaceutical

How Radioisotopes Are Being Used to De-Risk Antibody-Drug Conjugate (ADC) Development

Radiopharmaceutical

Why PDX Models Are Essential for Radiopharmaceutical Testing

A DNA helices showing the power of data in oncology drug discovery.

LUMIN

Beyond TCGA: TumorGraft’s New Frontier in Cancer Research

IHC

Predicting ADC Efficacy Using IHC and NGS

Bispecific antibody binding target protein on the tumor cell surface.

Immuno-Oncology

Advancements in bispecific antibody research and innovative platforms

Prev 1 2 3 4 5 Next

Corporate Headquarters
One University Plaza
Suite 307
Hackensack, NJ 07601

USA Research Operations
1330 Piccard Drive
Suite 025 & Suite 104
Rockville, MD 20850

Bioinformatics & Computational Biology Research Operations
40 Tuval St., Sapir Building 40th Floor,
Ramat Gan 5252247, Israel

© 2025, Champions Oncology, Inc
All rights reserved
Legal Notice | Privacy Policy